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Abstract
Background: Development of type 2 diabetes mellitus (T2DM) is determined by the interactions of genetic and
environmental factors. This study was designed to evaluate the possible role of VDR single nucleotide
polymorphisms (SNPs) on different aspects of diabetic host response (anthropometric, metabolic, oxidative stress
and inflammatory) to daily intake of vitamin D through fortified yogurt drink for 12 weeks.
Methods/Design: This study comprises two parts: (i) a case-control study; and (ii) an intervention trial. In the first part,
VDR polymorphisms (Taq1, FokI, Apa1, Bsm1,a n dCdx2) are determined in 350 T2DM patients and 350 non-diabetic
subjects. In the second part, the possible effects of daily intake of two servings of vitamin D3-fortified yogurt drink (FYD;
500 IU vitamin D/250 mL) on some selected metabolic (including insulin resistance), inflammatory and oxidative stress
biomarkers in 135 T2DM patients are assessed. To relate the resulted changes in the biomarkers to vitamin D
replenishment, another group of diabetic patients (n = 45) are also included in the study who receive 2 servings of
plain yogurt drink (PYD) a day. The primary outcome is serum level of 25(OH) D, which it is expected to be elevated
only in FYD group. Secondary outcomes include improvements in glycemic, metabolic, inflammatory and oxidative
stress biomarkers in FYD group compared to PYD group. Three VDR FokI polymorphisms are determined only in FYD
group followed by comparison of changes in the biomarkers among these genotypic variants.
Discussion: The present study, at least in part, elucidates the discrepancies in the results of different vitamin D-diabetes
studies pertaining to the genetic variations of the population. If VDR polymorphisms are found to influence the
response to our intervention, then knowing distribution of VDR polymorphisms in both diabetic and non-diabetic
populations can give a picture of the proportion of the community in whom up to 1000 IU/d vitamin D may not be
effective enough to improve insulin resistance and related morbidities. Therefore, they should ideally receive further
nutritional support according to their genotype.
Trial Registration: ClinicalTrials.gov: NCT01236846
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Type 2 diabetes mellitus (T2DM) is a global epidemic
costly condition [1]. Individuals with diabetes sustain
reduction in quality of life, and high prevalence of
mortality [2].
Development of T2DM is determined by the interac-
tions of genetic and environmental factors [3,4]. Most, if
not all, genetic influences have a polymorphic nature
[5,6]. A number of loci have been studied so far to
explain the genetic susceptibility to T2DM. An Example
is genes associated with glucokinase, hepatocyte nuclear
factors, insulin promoter factors, possibly the insulin
and insulin receptor genes and mitochondrial genes [7].
Among interesting, and less studied, diabetes-related
genes are those associated with vitamin D metabolism.
Apart from its calcemic effects, vitamin D is now known
to have many non-calcemic functions through which it
may have some role in several human pathologies includ-
ing some forms of cancers [8], autoimmune disorders [9],
obesity [10], metabolic syndrome [11] and both types 1
and 2 diabetes [12,13], among the others. Animal studies
have shown impaired insulin secretion [14] and action
[15,16] in vitamin D deficiency. Though vitamin D replen-
ishment of type 2 diabetics has been shown to improve
inflammatory biomarkers and glycemic control [17-23],
some studies failed to demonstrate these beneficial effects
[24,25]. The reasons for these discrepancies in results
could be numerous including sample size, duration and
mode of intervention (supplementation, injection, fortifica-
tion, or...) and dosages used, baseline values of 25(OH)D
and also of the other variables (glucose, lipids and so on),
method of vitamin D assessment (RIA, CPBA, CL or
HPLC) and finally genetic makeup of the study population.
The active form of vitamin D acts through a specific
vitamin D receptor (VDR) [26]. Allelic differences in the
VDR gene may contribute to the genetic predisposition
to certain diseases [10]. Research findings on associa-
tions among VDR polymorphisms, vitamin D stats,
T2DM and glycemic status have not been unanimous;
some confirmed such relations [18] and some did not
[25]. Nevertheless, as VDR has been recently found on
pancreatic beta cells [24], it is plausible that genetic var-
iants of the VDR gene may contribute to the develop-
ment of T2DM. There is a mere paucity of controlled
clinical trials on vitamin D and T2DM. On the other
hand, the findings of a few trials have been inconsistent.
Those studies mostly used either vitamin D injection
(monthly or weekly high dose injection) [27,28] or sup-
plements [16,29,30] (usually with dosages less than the
amount believed to be sufficient [31]). In the present
study we are going to use yogurt drink, which is an Ira-
nian drink (Persian name: Doogh), for vitamin D fortifi-
cation. Using fortified foodstuffs have the advantage of
lower cost and higher compliance [32]. Considering the
common nature of T2DM with obesity-induced insulin
resistance and metabolic syndrome [33], two conditions
with growing occurrence which may lead to T2DM [34],
using vitamin D3-fortified yogurt drink, if proved to be
effective in this study, can be encouraged as a preventive
tool. This idea must be substantiated by further cohort
studies.
This study was designed to evaluate the possible role
of VDR single nucleotide polymorphisms (SNPs) on dif-
ferent aspects of diabetic host response (anthropometric,
metabolic, oxidative stress and inflammatory) to daily
intake of vitamin D through fortified yogurt drink for
12 weeks.
Specific Aims
This study comprises two parts. The first part aims to
quantify the magnitude of association between any
identified variants of the VDR gene and T2DM. A
cross-sectional study is employed to compare distribu-
tion of each genotype of VDR polymorphisms in 350
type 2 diabetic adults and 350 non-diabetic controls.
T h es e c o n dp a r ti so u t l i n e dt oc o m p a r ew i t h i n -a n d
between-polymorphic group variations of host
response to daily intake of vitamin-D3-fortified yogurt
drink in terms of anthropometric, metabolic, inflam-
matory and oxidative stress markers.
Part 1
Primary Objectives
To determine distribution of VDR gene polymorphism
genotypes (Taq1, FokI, apa1, Bsm1, Cdx1)i nT 2 D M
patients and non-diabetic volunteers and to compare
between these two groups
Secondary Objectives
To determine distribution of VDR gene polymorphism
haplotypes (Taq1, FokI, Apa1, Bsm1, Cdx2)i nT 2 D M
patients and non-diabetic controls and to compare
between these two groups
Hypothesis
(i) There is a difference in prevalence of vitamin D
receptor gene polymorphisms between diabetics and
non-diabetic controls
( i i )T h e r ei sad i f f e r e n c ei np r e v a l e n c eo fv i t a m i nD
receptor gene polymorphism haplotypes between dia-
betics and non-diabetic controls
Part 2 study
Primary Objectives
To compare within- and between-polymorphic group
variations in circulating 25(OH)D in diabetic subjects
and also between diabetics and non-diabetic subjects.
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(i) To compare within- and between-polymorphic group
variations in anthropometric, metabolic, inflammatory
and oxidative stress biomarkers
(ii) To conduct an exploratory analysis of changes in
mean of anthropometric, metabolic, inflammatory and
oxidative stress biomarkers in FYD group among sub-
groups defined by genotypes of each VDR polymorphisms.
Hypothesis
(i) Daily consumption of vitamin D3-fortified-yogurt
drink improves serum 25(OH)D in type 2 diabetic
patients.
(ii) Daily consumption of vitamin D3-fortified-yogurt
drink improves biomarkers of anthropometric, meta-
bolic, inflammatory and oxidative stress in type 2 dia-
betes patients.
(iii) Response to daily consumption of vitamin-D3-forti-
fied yogurt drink differ between VDR polymorphic variant
groups
Methods/Design
Part 1
Participants
A case-control study is designed to compare VDR gene
polymorphism distribution between T2DM and age-,
sex- and body mass index (BMI)-matched non-diabetic
subjects. T2DM patients are recruited from two centers;
Iranian Diabetes Society and Gabric Diabetes Society,
both located in Tehran. Diabetic subjects are recruited
either by attending the clas s e sh e l da tt h et w oc e n t e r s
and verbal invitation or through phone call. Non-diabetic
controls are enrolled from school teachers, workers of
Tehran or Shahid Beheshti Universities and Pegah Dairy
Companies, all located in Tehran.
Full information on the study design and objectives of
the study is given to all participants before they sign an
informed written consent.
Sample Size
For observational study the sample size needed to obtain
90% power at a 5% significance level with an equal
number of case and controls for the chi-square test on
genotypes, is 350 at each group of cases and controls.
The sample size is calculated using the software Quanto:
http://hydra.usc.edu/gxe/.
Blood sampling
Fasting venous blood samples are collected into tubes
either with or without anticoagulant (ethylene diamine
tetra-acetate, EDTA). The anticoagulated tube is used to
extract genomic DNA while the sera from clot samples
are analyzed for glucose and lipids. Further information
about blood sampling and genotyping are in part 2
study in detail.
Variables
Information on demographic, medical history, physical
activity, duration of direct sun exposure and smoking
habits are gathered using questionnaires and face-to-
face interview. Anthropometric measures are taken in
the same meeting. Table 1 shows the study variables.
Value of results
This is the first study on the distribution of VDR SNPs
among type 2 diabetics and their possible relations to
the particular phenotypes in Iran. These data assist both
to the better understanding of vitamin D-T2DM inter-
relationships and to the preventive programs.
Part 2
This is a 3-month randomized controlled clinical trial
(RCT) in which T2DM patients aged 30-60 years are
enrolled. The study design is presented in Figure 1.
Setting
T h ep o s s i b l ee f f e c t so fd a i l yi n t a k eo ft w os e r v i n g so f
vitamin D3-fortified yogurt drink on some selected
metabolic (including insulin resistance), inflammatory
and oxidative stress biomarkers in T2DM patients (n =
135) are assessed. To relate the resulted changes in the
biomarkers to vitamin D replenishment, another smaller
group of diabetic patients (n = 45) are also included in
the study who receive 2 servings of plain yogurt drink a
day. To minimize endogenous vitamin D synthesis, the
entire intervention is confined to cold seasons (fall and
winter) of the year. The RCT is conducted collabora-
tively by National Nutrition and Food Technology
Research Institute (NNFTRI) and Tehran University of
Medical Sciences (TUMS) in Tehran, the capital of Iran.
Participants
T2DM patients are recruited from Iranian Diabetes
Society or Gabric Diabetes Society as described in the
first part of the study. Volunteers are invited to attend
Laboratory of Nutrition Research at NNFTRI while they
are fasting. Data gathering, bleeding and urine sampling
all are done during 07.30 and 10.00 am.
Inclusion criteria
1. Having type 2 diabetes
2. Willingness to participate
3. BMI between 25 to 35 kg/m
2
4. Age: 30-60 years old
5. No use of any vitamin, dietary, herbal or omega-3
supplements since at least 3 months to and during
the intervention period
Exclusion criteria
1. History of cardiovascular, gastrointestinal, renal,
and other endocrinological diseases
2. Subjects receiving vitamin D, omega-3 or other
types of dietary supplements
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4. Treatment with insulin
5. Treatment for weight reduction
6. Treatment for reducing serum cholesterol
Sample Size
Based on data on serum 25(OH)D changes from other
studies [35], to achieve 1 standard deviation difference
in circulating 25(OH)D with two-sided alpha of 0.05
and a beta of 0.2 after a 12-week intervention period,
the sample size was calculated 40 individuals per treat-
ment group. Considering 3 polymorphic variant groups
and one control group which receives plain yogurt
drink, 160 subjects are needed. Allowing for 10% attri-
tion over 12 weeks of intervention, a total of 180 sub-
jects are required.
Run-in
On the first visit and following completion of the ques-
tionnaires, all participants are given some general infor-
mation on diabetic diet, based on American Dietetic
Association (ADA) guidelines [36], with special focus on
fruits, vegetables and dairy intakes. Patients are
instructed not to change their usual physical activity
and to include 2-3 exchanges of fruits, 2 exchanges of
vegetables and 2-3 exchanges of low-fat milk exchanges
in their daily diet for the next 2 weeks (run in period).
Randomization/Blinding
After run-in period, participants are assigned randomly
to one of the treatment groups of either fortified yogurt
drink (FYD, n1 = 135) or plain yogurt drink (PYD, n2 =
45) using permuted blocks of random numbers alloca-
tion method. Letter codes A and B are used to identify
two groups, respectively. Yogurt drinks are identical in
color, size, taste and packaging. Therefore, participants
are not aware of their group, neither are all the inter-
viewers and laboratory staff. However, the main investi-
gators could not be technically blind to the identity of
the letter codes.
The randomization and labeling process are audited
halfway through the study by an observer to find if it is
robust, accurate and able to maintain blinding of
participants.
Intervention
Yogurt drinks are either plain (PYD; containing 170 mg
calcium and no vitamin D/250 mL) or vitamin D3-fortified
(FYD; containing 170 mg calcium and 500 IU vitamin
D3/250 mL). Participants are instructed to consume a bot-
tle of yogurt drink with both lunch and dinner, i.e.
500 mL/d equaling 1000 IU vitamin D3 ad a yi nF Y D
group. The intervention period is 12 weeks. Consumption
of 1000 IU/d vitamin D is believed to be safe and effective
to increase circulating 25(OH)D [13,37,38]. Participants
are given yogurt drinks in 30-bottle packs, which are
enough for 2 weeks. All subjects are visited biweekly to
both assess their compliance and provide them with
yogurt drinks for the next two weeks. Blood pressure,
anthropometric, dietary, body fat and laboratory evalua-
tions are preformed both before and after intervention.
Data comparison are made between PYD and FYD groups
and also, in FYD group, among VDR polymorphic groups.
Compliance
All participants are given a pamphlet on “instructions to
use yogurt drinks” together with a “yogurt drink con-
sumption table” comprised of 28 empty boxes for each
week. Subjects are instructed to mount the table in an
exposed place (preferably on refrigerator) and to tick
each box after consumption a yogurt drink with each
meal. Moreover, they are asked to bring the empty bot-
tles back on their next visit. Compliance is evaluated by
checking the consumption tables, counting the empty
bottles, direct enquiry both on the biweekly visits and
weekly follow-up phone calls.
Quality control of product
Composition (including vitamin D3) of the yogurt drinks
are measured right after production, in the middle and
end of the storage, to ensure the stability of the
Table 1 Study measures
Variable Methods
General data
Demographic data Questionnaire
Medical history Questionnaire
Sun exposure Questionnaire
Anthropometric and clinical data
Height, weight, waist and hip circumference Stadiometer, digital scale (Seca 840, Germany)
Blood pressure A digital sphygmomanometer (BC08, Beurer, Germany).
Blood data
Fasting plasma glucose, lipid profile Pars Azmoon, Tehran, Iran
Complete blood cell count Mythic, Orphe’e, France
VDR gene polymorphisms PCR-RFLP, Corbett Rotor-Gene 6000 instrument (Corbett Life Science)
Shab-Bidar et al. BMC Endocrine Disorders 2011, 11:12
http://www.biomedcentral.com/1472-6823/11/12
Page 4 of 10components, especially vitamin D, in the product. The
measurements are done by Maad Laboratory of Foods,
Drinks and Cosmetics, accredited by the Deputy of Food
and Drug of the Iranian Ministry of Health.
Outcome Measurements
Dietary assessment A semi-quantitative Food Fre-
quency Questionnaire (sqFFQ) and 24-h dietary recall
for 3 days (including a weekend day) are used for assess-
ment of dietary intake.
Anthropometry and Blood Pressure Body weight is
measured with light clothes without shoes using a digital
scale (Seca 808, Germany) to the nearest of 0.1 kg.
Height is measured using a stadiometer (Seca, Germany)
to the nearest of 0.1 cm. BMI is calculated by dividing
Figure 1 A summary of the interventional study.
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(WC) is measured in the midpoint of the lowest rib and
iliac crest in the end of expiration using a measuring
tape to the nearest of 0.1 cm
To measure blood pressure (BP), subjects are allowed
to be in sitting position at least 10 minutes. BP is mea-
sured twice by a digital sphygmomanometer (BC08,
Beurer, Germany). The average of the two measure-
ments is considered as subject’s BP.
Body Composition Analysis The percentage of body fat
is evaluated using bioelectrical impedance analysis
(Quadscan 4000 system, Bodystat, UK).
Laboratory investigations
All laboratory analyses are performed at the Laboratory
of Nutrition Research, NNFTRI.
Blood sampling and handling
Twenty mL of fasting venous blood taken from all parti-
cipants by phlebotomy is divided in three tubes: (i) a
micotube with an anticoagulant, EDTA; (ii) a heparinized
15-mL sterile capped plastic tube; and (iii) a clean glass
test tube without anticoagulant. Of about 500 μLE D T A -
blood sample in the microtube, 9 μLi su s e df o rC B C .
Heparinized blood sample is used for PBMC separation
and culture while the clot blood samples are kept for ~30
at RT followed by centrifugation at 1500 g at RT. Sera
thus recovered are transferred to clean micro-tubes in
aliquots. One aliquot is used to determine fasting serum
glucose (FSG) and lipid profile in the same day of bleed-
ing while the other tubes are kept at -80°C until the day
of analysis.
Hemoglobin and hematocrit
Hemoglobin and hematocrit are measured as parts of
complete blood cell count (CBC) test in the same day of
blood sampling by a cell-counter system (Mythic, Orphee,
France).
Blood chemistry
Fasting serum glucose (FSG), lipid profile including tri-
glycerides (TG), total cholesterol, low-density lipopro-
tein cholesterol (LDL-C), and high-density lipoprotein
cholesterol (HDL-C), alanine aminotransferase (ALT),
aspartate aminotransferase (AST) and uric acid are
determined using enzymatic methods. Serum total pro-
tein, albumin, calcium, phosphorous and magnesium are
measured by colorimetric assays. All these tests are
done by commercial kits (all from Pars Azmoon, Iran)
using an auto-analyzer system (Selectra E, Vitalab, the
Netherlands).
Glycated hemoglobin (HbA1c) is determined using
colorometric method after an initial chromatographic
separation (BioSystems, Spain).
Serum insulin levels are measured by immunoradio-
metric assay (IRMA) using a commercial kit (Biosource,
Belgium) and a g-counter system (Gamma I, Genesys,
USA).
Insulin resistance is evaluated by Quantitative Insulin
Check Index (QUICKI) calculated as [39]:
QUICKI: 1/[log (insulin) (μU/mL) + log (glucose)
(mg/dL)]
Serum 25(OH)D concentrations are measured by
HPLC method as described elsewhere [40]. Serum intact
parathyroid hormone (iPTH) (DRG, Germany) and
osteocalcin (Biousource, Belgium) concentrations are
determined using enzyme immunoassay (EIA).
In this study oxidative stress is evaluated by determina-
tion of serum glutathione, glutathione peroxidase, glu-
tathione reductase, superoxide dismutase (all from Bender
Medsystems, Austria), total antioxidant capacity (TAC)
using colorometic method with ABTS reagent and bovine
serum albumin as standard, as reported earlier [41] and
malondialdehyde (MDA), as described originally [42] with
some modifications [43].
Inflammatory status is evaluated using determination of
highly sensitive C-reactive protein (hsCRP) (immunoturbi-
dometric assay, Pars Azmoon, Iran), serum amyloid A
(SAA), endothelin-1 (both from IBL, Germany), E-selectin
and matrix metalloproteinase (MMP)-9 (both from
e-Bioscience, Austeria).
Urinary tests
Urinary sodium and potassium are measured by flame
photometry (Corning 480; Corning Ltd, Halstead, Essex,
UK). Urinary albumin and Creatinine are determined by
immunoturbidometric and colorometic methods, respec-
tively (both from Pars Azmoon, Iran) with the aid of an
auto-analyzer (Selectra E, Vitalab, the Netherlands).
PBMCs culture
Peripheral blood mononuclear cells (PBMC) were sepa-
rated using Ficoll-hypaque gradient density centrifugation
and cultured as described elsewhere [44] with minor mod-
ifications. In this study, ~10
6 cells are transferred to a cul-
ture well in a 6-well cell culture plate (Greiner bio-one,
Germany), each well containing 1% phytohemmaglutinin
(PHA) (Gibco), 100 ng/mL lipopolysaccharide (LPS)
(Gibco), 100 U/mL penicillin G and 10 ng/mL streptomy-
cin (both from Sigma-Aldrich) in a total volume of 2 mL
RPMI 1640. PBMC culture is performed in triplicate.
Cytokine assay
Concentrations of interleukin (IL)-2, IL-4, IL-6, IL-10
and tumor necrosis factor (TNF)-a (all from Bender
Medsystems, Austria) are determined in PBMCs culture
supernatant. All EIA tests are performed with the aid of
a microplate reader (Statfax 3200, Awareness, USA).
DNA extraction
Whole blood collected in a microtube containing 20 μL
7% EDTA are processed using Genet Bio DNA Isolation
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dures detailed in the kit to extract genomic DNA. Stock
D N Ai ss t o r e da t- 2 0i nal i n k e da n o n y m i z e df o r m a t ,
with codes held by principal investigators.
DNA genotyping
The VDR genotypes at BsmI, TaqI, ApaI, FokI and
Cdx-2 SNP sites are determined using polymerase
chain reaction (PCR)-restriction fragment length poly-
morphism (RFLP) analysis as described below. We use
a gradient palm-cycler (Corbett Research, Australia)
for PCR amplification. The purified primers (Fermen-
tase) and Premixes (Cinnagen) are purchased. Specific
primers are selected and validated for SNPs (table 2)
[45-47]. We use BLAST search (http://www.ncbi.nlm.
nih.gov/BLAST) to check the specificities and homol-
ogy percent of primers for the VDR sequence. All pri-
mers show 99% homology to the sequence in specific
region of the VDR gene.
Data management
For the better quality and accuracy of data, real time
data entry is ensured. We use manual checking of fre-
quencies during data entry. For primary analysis, alpha-
betical codes for groups are used still blinded to the real
group identity.
Statistical analyses
Data are expressed as mean ± SD. Normality of data
distribution is evaluated using Kolmogrov-Smirnov.
Comparison of data between two groups is done by
either student t test (normal distribution) or Mann-
Whitney U (not normal distribution).
Genotype distribution of the 5 VDR SNPs in the study
population is evaluated for Hardy-Weinberg equilibrium
by Chi square test. Odds ratios (OR) are given with 95%
confidence intervals (CI). Haplotypes frequencies and
distributions are estimated with a program based on EH
(estimating haplotypes)[48]. Haplotypes are compiled as
combinations of the 3 SNPs (BsmI, TaqI, ApaI).
The differences in distribution of the biomarkers among
p o l y m o r p h i cv a r i a n tg r o u p sa r ec o m p a r e db ya n a l y s i so f
variance (ANOVA) and, in the case of significant differ-
ence, Tukey’s post hoc analysis. A p value < 0.05 is consid-
ered significant. Correlation between two sets of data is
evaluated using either Pearson (normal distribution) or
Spearman (not normal distribution) equations. Multiple
linear regression modeling is used to identify the contribu-
tions of each independent variable to the variation of
response to vitamin D supplementation.
Data Validation
Data cleaning takes place by a series of logical checks on
the electronic data. Discrepant records are checked with
the source documents and the database is amended, if
necessary.
Ethical issues
The study protocol has been approved by the NNFTRI
(No. 035360), Shahid Beheshti University of Medical
Science, and by Tehran University of Medical Sciences
(TUMS) (No.10533) Ethical committees.
Table 2 VDR polymorphisms and PCR-RFLP information
SNP Localization Base
change
Nomenclature Forward primer/
reverse primer
Amplicone Restriction
site
Digestion
fragments
Genotype Restriction
enzyme
Reference
FokI Exon 2 C/T FF
Ff
ff
5’-AgC Tgg CCC Tgg
CAC TgA CTC TgC
TCT-3’
5’-ATg gAA ACA CCT
TgC TTC TTC TCC
CTC-3’
265 CC
CT
TT
207-60 mut
ht
wt
FokI [45]
BsmI Intron 8 G/A BB
Bb
bb
5’-ggC AAC CTg AAg
ggA gAC gTA-3’
5’-CTC TTT ggA CCT
CAT CAC CgA C-3’
461 AA
GA
GG
258-253 mut
ht
wt
Mva 1269I [46]
TaqI Exon 9 T/C TT
Tt
tt
5’-CAg AgC ATg gAC
Agg gAg CAA g-3’
5’-gCA ACT CCT CAT
ggC TgA ggT CTC A-
3’
740 TT
TC
CC
495-245-
290-205
wt
ht
mut
TaqI [45]
ApaI Intron 8 G/T AA
Aa
aa
5’-CAg AgC ATg gAC
Agg gAg CAA g-3’
5’-gCA ACT CCT CAT
ggC TgA ggT CTC A-
3’
740 TT
GT
GG
515-225 mut
ht
wt
Bsp120I [45]
Cdx-
2
Intron 1e G/A CC
Cc
cc
5’-CAg CAT gCC TgT
CCT CAg C-3’
5’-CCA gTA CTg CCA
gCT CCC-3’
250 AA
GA
GG
mut
ht
wt
Bpu10I [47]
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Increasing evidences suggest a pivotal role for vitamin D
in insulin action [15,16] and T2DM [12,13]. However,
the results of vitamin D supplementation in diabetics
have not been consistent [20,25]. The reasons for this
inconsistency could be the vitamin D dosage and route
of administration (injection [27,28] vs. oral [30]), age of
the study population (middle aged [49] vs. elderly [50])
and probably genetic variations. The role of VDR poly-
morphism in response to vitamin D interventions has
been reported in other clinical settings [51,52]. The con-
tribution of VDR polymorphism in susceptibility to
T2DM has also been shown in some studies recently
[ 1 8 ] .H o w e v e r ,t h i si st h ef i rst clinical trial on the role
of VDR polymorphism in response to vitamin D replen-
ishment on different aspects of diabetic pathology,
including anthropometric, metabolic, oxidative stress,
inflammatory and immunity. This study pursues three
objectives: Firstly, to tackle relationship between VDR
genotypes and T2DM for the first time in Iranian popu-
lation; secondly, to elucidate the potential mechanisms
and cross-talk among pathways, by which vitamin D
exerts its effects on diabetes, insulin resistance and car-
diovascular disease by evaluating an extensive panel of
biomarkers (anthropometric, metabolic, inflammatory
and oxidative stress); and finally to identify vitamin D
responsive vs. less or (maybe) non-responsive VDR
genetic variants in subjects with T2DM for further
proper nutritional care.
The following points can be considered as the strengths
of this study: i) the intervention is conducted during cold
seasons, when dermal synthesis, especially at Tehran lati-
tude, is minimal[53]; ii) various degrees of vitamin D
deficiency have been shown to be prevalent in Iranian
general population at almost all ages [54] as well as dia-
betics [21]. Because of lower basal 25(OH)D levels, the
response to vitamin D replenishment is expected to be
more prominent; iii) yogurt drink, a popular Iranian
drink, is used to fortify with vitamin D for the first time.
The results of this study will show the bioavailability of
vitamin D in this drink. Moreover, apart from the added
vitamin D, yogurt drink protein and calcium content
makes it a very good choice and a substitute for sugar-
free colas and even juices in diabetic, as well as a variety
of non-diabetic, diets; iv) the dosage of vitamin D [55]
and duration of intervention [56] seem to be proper.
The present study, at least in part, elucidates the discre-
pancies in the results of different vitamin D-diabetes stu-
dies pertaining to the genetic variations of the population.
On the other hand, the importance of the upcoming
results lies on the fact that both metabolic syndrome and
obesity-induced insulin resistance, two conditions with
increasing global occurrences which predispose T2DM
development [33], have similar pathologic bases [34]. If
VDR SNPs are found to influence the response to our
intervention, then knowing distribution of VDR poly-
morphisms in both diabetic and non-diabetic populations
can give a picture of the proportion of the community in
whom up to 1000 IU/d vitamin D may not be effective
enough to improve insulin resistance and related morbid-
ities. Therefore, they should ideally receive further nutri-
tional support according to their genotype.
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